X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs ALKEM LABORATORIES - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD ALKEM LABORATORIES LUPIN LTD/
ALKEM LABORATORIES
 
P/E (TTM) x 19.9 - - View Chart
P/BV x 2.7 7.4 36.4% View Chart
Dividend Yield % 0.9 0.6 159.0%  

Financials

 LUPIN LTD   ALKEM LABORATORIES
EQUITY SHARE DATA
    LUPIN LTD
Mar-17
ALKEM LABORATORIES
Mar-16
LUPIN LTD/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,7501,589 110.1%   
Low Rs1,3841,232 112.3%   
Sales per share (Unadj.) Rs387.4417.5 92.8%  
Earnings per share (Unadj.) Rs56.656.3 100.6%  
Cash flow per share (Unadj.) Rs76.864.7 118.7%  
Dividends per share (Unadj.) Rs7.5012.70 59.1%  
Dividend yield (eoy) %0.50.9 53.2%  
Book value per share (Unadj.) Rs298.9292.9 102.0%  
Shares outstanding (eoy) m451.58119.57 377.7%   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x4.03.4 119.7%   
Avg P/E ratio x27.725.1 110.4%  
P/CF ratio (eoy) x20.421.8 93.5%  
Price / Book Value ratio x5.24.8 108.9%  
Dividend payout %13.222.6 58.7%   
Avg Mkt Cap Rs m707,513168,653 419.5%   
No. of employees `00016.8NA-   
Total wages/salary Rs m28,4959,171 310.7%   
Avg. sales/employee Rs Th10,418.3NM-  
Avg. wages/employee Rs Th1,697.0NM-  
Avg. net profit/employee Rs Th1,523.0NM-  
INCOME DATA
Net Sales Rs m174,94349,915 350.5%  
Other income Rs m1,0651,645 64.7%   
Total revenues Rs m176,00851,561 341.4%   
Gross profit Rs m44,9318,482 529.7%  
Depreciation Rs m9,1221,006 907.0%   
Interest Rs m1,525671 227.5%   
Profit before tax Rs m35,3498,451 418.3%   
Minority Interest Rs m-72-114 63.0%   
Prior Period Items Rs m830-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m9,7851,606 609.3%   
Profit after tax Rs m25,5756,731 379.9%  
Gross profit margin %25.717.0 151.1%  
Effective tax rate %27.719.0 145.7%   
Net profit margin %14.613.5 108.4%  
BALANCE SHEET DATA
Current assets Rs m119,54227,062 441.7%   
Current liabilities Rs m61,20615,324 399.4%   
Net working cap to sales %33.323.5 141.8%  
Current ratio x2.01.8 110.6%  
Inventory Days Days7667 114.3%  
Debtors Days Days9041 217.7%  
Net fixed assets Rs m131,66012,610 1,044.1%   
Share capital Rs m903239 377.7%   
"Free" reserves Rs m134,07334,490 388.7%   
Net worth Rs m134,97635,027 385.4%   
Long term debt Rs m56,4781,212 4,661.4%   
Total assets Rs m266,07354,387 489.2%  
Interest coverage x24.213.6 177.7%   
Debt to equity ratio x0.40 1,209.6%  
Sales to assets ratio x0.70.9 71.6%   
Return on assets %10.213.6 74.8%  
Return on equity %18.919.2 98.6%  
Return on capital %19.324.9 77.5%  
Exports to sales %012.9 0.0%   
Imports to sales %03.1 0.0%   
Exports (fob) Rs mNA6,461 0.0%   
Imports (cif) Rs mNA1,540 0.0%   
Fx inflow Rs m81,8856,563 1,247.6%   
Fx outflow Rs m21,5063,012 714.1%   
Net fx Rs m60,3783,552 1,700.0%   
CASH FLOW
From Operations Rs m41,1487,259 566.9%  
From Investments Rs m-25,2871,864 -1,356.4%  
From Financial Activity Rs m4,332-9,273 -46.7%  
Net Cashflow Rs m20,193-150 -13,461.7%  

Share Holding

Indian Promoters % 46.6 66.9 69.7%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 33.1 34.1%  
FIIs % 31.9 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 0.0 -  
Shareholders   98,259 68,381 143.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   GSK PHARMA  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  IPCA LABS  NATCO PHARMA  

Compare LUPIN LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Feb 23, 2018 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD - SUVEN LIFE COMPARISON

COMPARE LUPIN LTD WITH

MARKET STATS